Tekla Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Tekla Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$7.95M	Buy	34,434 +21,953	+176%	+$5.95M	0.31%	66
2023 Q1	$3.02M	Buy	+12,481	New	+$3.4M	0.12%	99
2021 Q3	–	Sell	-13,340	Closed	-$1.3M	–	187
2021 Q2	$1.3M	Hold	13,340	–	–	0.04%	167
2021 Q1	$1.56M	Hold	13,340	–	–	0.05%	170
2020 Q4	$1.48M	Hold	13,340	–	–	0.05%	170
2020 Q3	$1.58M	Hold	13,340	–	–	0.06%	163
2020 Q2	$1.51M	Hold	13,340	–	–	0.06%	177
2020 Q1	$891K	Hold	13,340	–	–	0.04%	182
2019 Q4	$1.22M	Hold	13,340	–	–	0.05%	177
2019 Q3	$1.15M	Hold	13,340	–	–	0.05%	154
2019 Q2	$1.4M	Hold	13,340	–	–	0.06%	151
2019 Q1	$1.67M	Buy	13,340 +6,670	+100%	+$829K	0.07%	139
2018 Q4	$752K	Hold	6,670	–	–	0.03%	175
2018 Q3	$1.43M	Buy	+6,670	New	+$1.67M	0.05%	170
2013 Q4	–	Sell	-13,993	Closed	-$3.09M	–	61
2013 Q3	$3.09M	Buy	13,993 +3,229	+30%	+$687K	0.34%	51
2013 Q2	$1.88M	Buy	+10,764	New	+$2.81M	0.26%	51

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Tekla Capital Management's MDGL Position: Q2 2023 in Review

Tekla Capital Management increased its Madrigal Pharmaceuticals (MDGL) stake by 176% in Q2 2023, buying an estimated $5.95M and bringing the position to 34,434 shares worth $7.95M. The position accounts for 0.31% of the portfolio, ranked #66.

Tekla Capital Management first reported a position in MDGL in Q2 2013 and has held it in 16 quarters since. 208 funds tracked by Wall St. Rank hold MDGL as of Q2 2023.

Tekla Capital Management held 34,434 shares of Madrigal Pharmaceuticals worth $7.95M as of Q2 2023.
Tekla Capital Management bought 21,953 Madrigal Pharmaceuticals shares in Q2 2023, an estimated $5.95M.
Madrigal Pharmaceuticals made up 0.31% of Tekla Capital Management's portfolio in Q2 2023, its #66 holding.
Tekla Capital Management first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
208 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.